Onconova technologies and products are developed utilizing our proprietary chemistry platform. Some of our product candidates are partnered with pharmaceutical or biotechnology companies for advanced development. We endeavor to retain a participating role as we expand our competency horizon to include commercialization capabilities.
To discuss partnering opportunities with Onconova please contact email@example.com.
SPECIALISED THERAPEUTICS ASIA
December 18, 2019 – Onconova entered into a Distribution, License and Supply Agreement with Specialised Therapeutics Asia (“STA”). Headquartered in Singapore, STA is an international biopharmaceutical company established to commercialize new therapies and technologies to patients throughout South East Asia, as well as in Australia and New Zealand. The Agreement grants STA the exclusive rights to commercialize rigosertib in Australia and New Zealand.
For more information please refer to the Press Release of Dec. 18, 2019
KNIGHT THERAPEUTICS INC.
November 21, 2019 – Onconova entered into a Distribution, License and Supply Agreement with Knight Therapeutics Inc., a Canadian-based specialty pharmaceutical company focused on acquiring, in-licensing, selling and marketing innovative prescription and over-the-counter pharmaceutical products. According to the Agreement, Knight shall have the exclusive rights to commercialize rigosertib in Canada.
For more information please refer to the Press Release of Nov. 21, 2019
Aug. 12, 2019 – Onconova entered into a Partnership with Mission Bio to advance precision oncology clinical trials employing single-cell genomics. The alliance will leverage Mission Bio’s Tapestri Platform to investigate Onconova’s novel cancer therapy rigosertib, through clinical trials.
For more information please refer to the Press Release of Aug. 12, 2019
March 5, 2018 – Onconova entered into a License Agreement with Pint Pharma GmbH to commercialize rigosertib in Latin America. Pint Pharma is a Europe based pharmaceutical company focused on the development, registration and commercialization of specialty-based treatments for the Latin American market.
For more information please refer to the Press Release of March 5, 2018
NATIONAL CANCER INSTITUTE/NATIONAL INSTITUTES OF HEALTH
Jan 04, 2018 – Onconova entered into a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI), part of the National Institutes of Health (NIH). Under the terms of the CRADA, the NCI will conduct research, including preclinical laboratory studies and a clinical trial, on rigosertib in pediatric cancer associated RASopathies.
For more information please refer to the Press Release of Jan. 4, 2018
HANX BIOPHARMACEUTICALS, INC.
Dec 19, 2017 – Onconova entered into a License and Collaborative Development Agreement with HanX Biopharmaceuticals, Inc. for the further development, registration, and commercialization of narazaciclib (ON 123300) in China. Narazaciclib (ON 123300) is a first-in-class dual inhibitor of CDK4/6 + ARK5, which is currently in a dose-escalation and expansion Phase 1 trial in China. This compound has the potential to overcome the limitations of current generation CDK 4/6 inhibitors.
For more information please refer to the Press Release of Dec. 19, 2017
SYMBIO PHARMACEUTICALS LIMITED
July 2011 – Onconova and SymBio Pharmaceuticals began a collaboration to develop and commercialize rigosertib in Japan and Korea. Under the terms of the agreement, SymBio has an exclusive license for Japan and Korea and will develop and commercialize rigosertib in these countries. Onconova received an upfront payment and will receive milestone payments tied to the progress of rigosertib development, as well as sales milestone payments plus royalties on net sales. Onconova supplies drug product for clinical trials conducted by SymBio in Japan.